Nakarmi Prami, Hermiz Joshua, Vempati Roopeessh, Chandna Sanya, Bhagat Umesh, Loree Stacy, Toquica Gahona Christian
Department of Internal Medicine and Cardiology, Trinity Health Oakland Hospital, Pontiac, USA.
Department of Internal Medicine, Cleveland Clinic Hospital, Cleveland, USA.
Eur J Case Rep Intern Med. 2025 May 6;12(6):005379. doi: 10.12890/2025_005379. eCollection 2025.
Minoxidil is a direct-acting vasodilator that reduces systemic vascular resistance by opening adenosine triphosphate (ATP)-sensitive potassium channels, leading to arteriolar smooth muscle vasodilation. While commonly prescribed for resistant hypertension and androgenic alopecia, minoxidil is associated with fluid retention, and in rare cases, pericardial effusion that can progress to cardiac tamponade. In this report, we present a case of an 81-year-old male with a history of chronic kidney disease (CKD) who developed cardiac tamponade while on chronic minoxidil therapy for hypertension. He presented with progressive dyspnoea, lower extremity oedema, and fever. Imaging revealed an enlarged cardiac silhouette, and a confirmatory echocardiogram demonstrated a pericardial effusion with right ventricular collapse. The patient underwent urgent pericardiocentesis, yielding 545 ml of pericardial fluid. Infectious, malignant, and autoimmune aetiologies were ruled out, and minoxidil was identified as the likely cause. Following discontinuation of minoxidil, the patient's symptoms completely resolved, with no recurrence at 1-month follow-up. In addition, we reviewed 26 previously reported cases of minoxidil-induced pericardial effusion and/or cardiac tamponade, 17 of which are summarized in this report. This case demonstrates the rare but potentially fatal complication of therapy and emphasizes the importance of early detection and clinical vigilance, particularly in vulnerable populations such as patients with CKD.
This case highlights minoxidil-induced cardiac tamponade - a rare but fatal adverse effect requiring urgent intervention, especially underrecognized in clinical practice.Patients with chronic kidney disease are at increased risk for minoxidil-induced pericardial effusion due to altered fluid regulation and renin-angiotensin-aldosterone system activation.Clinicians should maintain a high index of suspicion and consider routine cardiac monitoring in minoxidil users, even for non-hypertensive indications such as hair loss.
米诺地尔是一种直接作用的血管扩张剂,通过打开三磷酸腺苷(ATP)敏感性钾通道降低全身血管阻力,导致小动脉平滑肌血管扩张。虽然米诺地尔常用于治疗顽固性高血压和雄激素性脱发,但它与液体潴留有关,在罕见情况下,会导致心包积液,进而发展为心脏压塞。在本报告中,我们介绍了一例81岁男性患者,他有慢性肾脏病(CKD)病史,在接受米诺地尔长期治疗高血压期间发生了心脏压塞。他出现进行性呼吸困难、下肢水肿和发热。影像学检查显示心脏轮廓增大,确诊性超声心动图显示心包积液伴右心室塌陷。患者接受了紧急心包穿刺,抽出545毫升心包积液。排除了感染、恶性和自身免疫病因,确定米诺地尔为可能病因。停用米诺地尔后,患者症状完全缓解,1个月随访时无复发。此外,我们回顾了26例先前报道的米诺地尔引起的心包积液和/或心脏压塞病例,其中17例总结在本报告中。该病例证明了治疗中这种罕见但可能致命的并发症,并强调了早期发现和临床警惕的重要性,特别是在像CKD患者这样的弱势群体中。
本病例突出了米诺地尔引起的心脏压塞——一种罕见但致命的不良反应,需要紧急干预,尤其是在临床实践中未得到充分认识。由于液体调节改变和肾素-血管紧张素-醛固酮系统激活,慢性肾脏病患者发生米诺地尔引起的心包积液的风险增加。临床医生应保持高度怀疑,并考虑对米诺地尔使用者进行常规心脏监测,即使是用于脱发等非高血压适应症。